Issue Archive

Peripheral T-cell lymphomas are rare and have poorer prognoses than more common B-cell lymphomas. It is therefore appropriate to highlight the current state of knowledge about this heterogeneous cluster of lymphoproliferative diseases. Associate Editor Philippe Armand introduces this series of 5 reviews covering the biology, diagnosis, and treatment of this multitude of distinct entities, including T-cell large granular lymphocytic leukemia.

Peripheral T-cell lymphomas are rare and have poorer prognoses than more common B-cell lymphomas. It is therefore appropriate to highlight the current state of knowledge about this heterogeneous cluster of lymphoproliferative diseases. Associate Editor Philippe Armand introduces this series of 5 reviews covering the biology, diagnosis, and treatment of this multitude of distinct entities, including T-cell large granular lymphocytic leukemia.

Peripheral T-cell lymphomas are rare and have poorer prognoses than more common B-cell lymphomas. It is therefore appropriate to highlight the current state of knowledge about this heterogeneous cluster of lymphoproliferative diseases. Associate Editor Philippe Armand introduces this series of 5 reviews covering the biology, diagnosis, and treatment of this multitude of distinct entities, including T-cell large granular lymphocytic leukemia.

Peripheral T-cell lymphomas are rare and have poorer prognoses than more common B-cell lymphomas. It is therefore appropriate to highlight the current state of knowledge about this heterogeneous cluster of lymphoproliferative diseases. Associate Editor Philippe Armand introduces this series of 5 reviews covering the biology, diagnosis, and treatment of this multitude of distinct entities, including T-cell large granular lymphocytic leukemia.

Peripheral T-cell lymphomas are rare and have poorer prognoses than more common B-cell lymphomas. It is therefore appropriate to highlight the current state of knowledge about this heterogeneous cluster of lymphoproliferative diseases. Associate Editor Philippe Armand introduces this series of 5 reviews covering the biology, diagnosis, and treatment of this multitude of distinct entities, including T-cell large granular lymphocytic leukemia.

Peripheral T-cell lymphomas are rare and have poorer prognoses than more common B-cell lymphomas. It is therefore appropriate to highlight the current state of knowledge about this heterogeneous cluster of lymphoproliferative diseases. Associate Editor Philippe Armand introduces this series of 5 reviews covering the biology, diagnosis, and treatment of this multitude of distinct entities, including T-cell large granular lymphocytic leukemia.

Al-Sawaf and colleagues report the 6-year results of the CLL14 study, a multicenter open label phase 3 trial for older treatment-naive patients with chronic lymphocytic leukemia and coexisting conditions, comparing 1-year fixed-duration venetoclax-obinutuzumab (VO) with chlorambucil-obinutuzumab. Five years after all patients completed therapy, 67% of patients who received VO have not required more therapy and 53% have not progressed, rates double that seen with the previous standard therapy, with the greatest incremental improvements seen in those with poor prognosis genetics. Patients who received VO have better quality of life, better global health status, and improved survival, with no significant excess of second cancers.

For patients with relapsed classical Hodgkin lymphoma (HL), checkpoint inhibitor therapy has high response rates, but most patients relapse within 5 years. Trialing an epigenetic-immunotherapy regimen consisting of the histone deacetylase inhibitor chidamide, decitabine, and the anti–PD-1 antibody camrelizumab, Nie et al report a 50% complete response rate and restored antitumor immunity in heavily treated patients, including those previously receiving anti–PD-1-based therapy. Through comprehensive single-cell analyses of longitudinal HL biopsies, they identify correlates of response and resistance, providing insights into both the biology of the disease and the activity of the regimen.

The use of ABL tyrosine kinase inhibitors (TKIs) means that survival of most patients with chronic myeloid leukemia (CML) approaches that of people without the disease, and consequently prospective identification of patients destined to fail TKI therapy is a research priority. Zhang and colleagues propose a scoring system to predict the risk of first-line TKI failure, which they validated in an independent cohort of more than 3400 patients with chronic-phase CML. Their system outperforms existing scores and identifies a high-risk group with a failure rate of >70% at 8 years for future attention.

As yet, there is no practical and robust blood diagnostic test for variant Creutzfeldt-Jakob disease (vCJD), a prion disease that can be transmitted by blood transfusion. Thomas et al report a comparative analysis of 3 highly specific blood assays to detect disease-associated prion protein in blood of sheep infected with bovine spongiform encephalopathy as a model of human vCJD. Their research will accelerate the development of a much-needed human vCJD blood assay.